<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68958">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02087540</url>
  </required_header>
  <id_info>
    <org_study_id>ID_Telotan_1203</org_study_id>
    <nct_id>NCT02087540</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia</brief_title>
  <official_title>A Randomized, Double-blind, Multi-center, Factorial Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify efficacy and safety of Telmisartan/Rosuvastatin co-administration in
      hyperlipidemia control in hypertensive patients with hyperlipidemia compared to each
      monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>â€¢Change in seated diastolicblood pressure at 8 weeks compared to the base value</measure>
    <time_frame>at the 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LDL-Cat 8 weeks compared to the base value (% change)</measure>
    <time_frame>at the 8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in seateddiastolic blood pressure</measure>
    <time_frame>at 2,4 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seated systolic blood pressure</measure>
    <time_frame>at 2,4,8weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients achieving a therapeutic purpose according to JNC VII Guideline [therapeutic purpose for blood pressure: &lt; 140/90 mmHg (however, &lt; 130/80 mmHg for Group III)]</measure>
    <time_frame>at 2, 4 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-Cat compared to the base value (% change)</measure>
    <time_frame>2, 4 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TC, TG, HDL-C and Apolipoprotein B compared to the base value (% change)</measure>
    <time_frame>at 2, 4 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients achieving a therapeutic purpose according to NCEP ATP III Guideline therapeutic purpose for LDL-C- (Group I:  &lt; 160 mg/dL, Group II: &lt; 130 mg/dL, Group III: &lt; 100 mg/dL)</measure>
    <time_frame>at 2, 4 and 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO, Once Daily, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO, Once Daily, 8weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once Daily, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan Placebo &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once Daily, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once Daily, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PO, Once Daily, 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg</intervention_name>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20mg</intervention_name>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 10mg</intervention_name>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_label>Telmisartan Placebo &amp; Rosuvastatin 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for Telmisartan 80mg)</intervention_name>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Telmisartan Placebo &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin placebo</arm_group_label>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for Rosuvastatin 20mg)</intervention_name>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_label>Telmisartan Placebo &amp; Rosuvastatin 10mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin placebo</arm_group_label>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(for Rosuvastatin 10mg)</intervention_name>
    <arm_group_label>Telmisartan 80mg &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin 20mg</arm_group_label>
    <arm_group_label>Telmisartan placebo &amp; Rosuvastatin placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Men and women &gt;18 years of age

          -  Subject who has one of 3 conditions classifed by Cardiovascular Risk Factors, 10-Year
             Risk, Blood Pressure, LDL-C, Coronary Artery Disease and Equivalent

        Exclusion Criteria:

          -  Female who are pregnant, breastfeeding, or of childbearing potential, unwilling to
             practice adequate contraception throughout the study,.

          -  Other exclusions applied
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Catholic University of Saint Mary's Hosiptal</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wook-seong chung, MD</last_name>
      <email>chungws@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>wook-seong Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>March 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
    <mesh_term>Benzoates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
